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Abstract:    Virus-like particles (VLPs) are generated by the self-assembly of viral structural protein using 
various expression systems. VLPs ensemble native virus particles in morphology and maintain key immune 
epitopes as authentic virus. In light of nanometer-sized particles with diameters of 20- 60 nm, VLPs were 
shown to be a passport to immune recognition, thus being capable of eliciting strong protective immune 
responses. Recombinant VLP-based vaccines have superior safety profiles due to lack of any viral genome. 
There are several licensed and highly successful VLP-based vaccines produced using recombinant DNA 
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technology, such as recombinant hepatitis B, human papillomavirus and hepatitis E vaccine. E.coli expression 
system was well-established in production of biotherapeutics.  This production platform for recombinant 
VLP-based vaccines has many advantages, such as rapid replication cycle and amenability for scale-up for 
commercial scale production. This review outlines the success of hepatitis E and human papillomavirus 
vaccines derived from E.coli. We highlight the protein expression, particle assembly, key epitope structure and 
clinical trials of these VLP-based vaccines.
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HPV6/11型双价疫苗(尖锐湿疣疫苗)均已进入了临
床试验阶段。















































































































































































































































































































































































































阴道、阴门瘤样病变 )保护率也是100％ (88%~ 
100%)[62]。
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